Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease (COPD)

In brief

This study assessed the efficacy and safety of indacaterol (150 µg once daily \[od\]) when combined with tiotropium (18 µg od) versus tiotropium (18 µg od) treatment alone in patients with chronic obstructive pulmonary disease (COPD).

Key facts

Study ID

NCT00877383

Run by

Novartis Pharmaceuticals

People needed

1142

Starts

2009-04-01

Expected to finish

2010-02-01

Last updated by the study team

2011-08-25

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:
• Smoking history of at least 10 pack-years
• Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value
• Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%

You may not qualify if…

• Patients who have received systemic corticosteroids and/or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
• Patients who have had a respiratory tract infection within 6 weeks prior to screening
• Patients with concomitant pulmonary disease
• Patients with a history of asthma
• Patients with diabetes Type I or uncontrolled diabetes Type II
• Any patient with lung cancer or a history of lung cancer
• Patients with a history of certain cardiovascular comorbid conditions
• Other protocol-defined inclusion/exclusion criteria applied to the study.

Where it is running

• Novartis Investigator Site — Birmingham, Alabama, United States
• Novartis Investigator Site — Jasper, Alabama, United States
• Novartis Investigator Site — Mobile, Alabama, United States
• Novartis Investigator Site — Glendale, Arizona, United States
• Novartis Investigator Site — Phoenix, Arizona, United States
• Novartis Investigator Site — Phoenix, Arizona, United States
• Novartis Investigator Site — Scottsdale, Arizona, United States
• Novartis Investigator Site — Little Rock, Arkansas, United States
• Novartis Investigator Site — Buena Park, California, United States
• Novartis Investigator Site — Fullerton, California, United States
• Novartis Investigator Site — Mission Viejo, California, United States
• Novartis Investigator Site — San Ramon, California, United States
• Novartis Investigator Site — Santa Barbara, California, United States
• Novartis Investigator Site — Sepulveda, California, United States
• Novartis Investigator Site — Spring Valley, California, United States
• Novartis Investigator Site — Torrance, California, United States
• Novartis Investigator Site — Torrance, California, United States
• Novartis Investigator Site — Vista, California, United States
• Novartis Investigator Site — Boulder, Colorado, United States
• Novartis Investigator Site — Centennial, Colorado, United States
• Novartis Investigator Site — Colorado Springs, Colorado, United States
• Novartis Investigator Site — Denver, Colorado, United States
• Novartis Investigative Site — Glastonbury, Connecticut, United States
• Novartis Investigative Site — Waterbury, Connecticut, United States
• Novartis Investigator Site — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.